Lyell Immunopharma, Inc.
LYEL
$11.02
-$0.79-6.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.96% | -262.62% | 12.33% | 28.30% | 9.40% |
| Total Depreciation and Amortization | -31.51% | -0.61% | -8.31% | -3.18% | -0.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -78.83% | 2,431.42% | -32.16% | -76.57% | -15.81% |
| Change in Net Operating Assets | -195.15% | -98.03% | -57.25% | -126.62% | 24.91% |
| Cash from Operations | -30.28% | -16.26% | 7.02% | 2.72% | 9.08% |
| Capital Expenditure | -720.00% | -76.00% | 69.74% | 64.52% | 98.04% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 216.53% | 184.33% | -98.02% | -70.53% | -34.62% |
| Cash from Investing | 215.84% | 153.14% | -98.08% | -70.57% | -31.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -50.45% | -100.00% | -30.82% | -- |
| Repurchase of Common Stock | -- | 100.00% | 100.00% | 100.00% | -10.14% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -96.30% | -42.42% | 100.00% | -27.93% | 139.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 173.66% | 104.77% | -153.56% | -93.24% | -41.54% |